See more : Keweenaw Financial Corporation (KEFI) Income Statement Analysis – Financial Results
Complete financial analysis of Royalty Pharma plc (RPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Royalty Pharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Catena Media plc (CTTMF) Income Statement Analysis – Financial Results
- SpineGuard SA (ALSGD.PA) Income Statement Analysis – Financial Results
- Shine Minerals Corp. (PAUFF) Income Statement Analysis – Financial Results
- Binhai Investment Company Limited (2886.HK) Income Statement Analysis – Financial Results
- Li-Metal Corp. (LIM.CN) Income Statement Analysis – Financial Results
Royalty Pharma plc (RPRX)
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.60B | 1.88B | 1.65B |
| Cost of Revenue | 560.66M | 5.67M | 23.00M | 88.11M | 1.02B | 135.96M | 33.27M | 0.00 | 0.00 |
| Gross Profit | 1.79B | 2.23B | 2.27B | 2.03B | 794.93M | 1.66B | 1.56B | 1.88B | 1.65B |
| Gross Profit Ratio | 76.19% | 99.75% | 99.00% | 95.85% | 43.82% | 92.43% | 97.92% | 100.00% | 100.00% |
| Research & Development | 52.00M | 177.11M | 200.08M | 26.00M | 83.04M | 392.61M | 117.87M | 91.02M | 98.38M |
| General & Administrative | 249.75M | 227.30M | 182.83M | 182.00M | 103.44M | 61.91M | 106.44M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 249.75M | 227.30M | 182.83M | 182.00M | 103.44M | 61.91M | 106.44M | 69.51M | 121.42M |
| Other Expenses | 560.66M | 909.91M | 475.84M | 319.00M | -995.40M | -1.52M | -1.62M | -925.80M | -570.18M |
| Operating Expenses | 862.40M | 1.31B | 858.75M | 527.00M | -808.92M | 430.45M | 658.24M | 1.09B | 789.98M |
| Cost & Expenses | 862.40M | 1.31B | 858.75M | 527.00M | -808.92M | 430.45M | 658.24M | 1.15B | 858.14M |
| Interest Income | 72.29M | 78.34M | 53.54M | 28.38M | 22.33M | 24.44M | 6.76M | 0.00 | 0.00 |
| Interest Expense | 187.19M | 187.96M | 166.14M | 157.00M | 268.57M | 279.96M | 247.34M | 238.92M | 224.42M |
| Depreciation & Amortization | 395.13M | 5.67M | 23.00M | 23.06M | 23.92M | 33.27M | 33.27M | 68.20M | 68.16M |
| EBITDA | 1.89B | 928.56M | 1.45B | 1.68B | 2.65B | 1.40B | 972.96M | 1.07B | 862.44M |
| EBITDA Ratio | 80.15% | 43.95% | 64.73% | 88.69% | 145.37% | 78.76% | 71.46% | 42.14% | 52.19% |
| Operating Income | 1.49B | 977.50M | 1.43B | 1.60B | 2.62B | 1.36B | 939.69M | 722.87M | 794.28M |
| Operating Income Ratio | 63.37% | 43.69% | 62.49% | 75.16% | 144.59% | 76.02% | 58.81% | 38.50% | 48.07% |
| Total Other Income/Expenses | 207.94M | -77.00M | -189.51M | 106.56M | -161.76M | 153.41M | 403.49M | 39.02M | -35.57M |
| Income Before Tax | 1.70B | 230.06M | 1.24B | 1.70B | 2.46B | 1.52B | 1.34B | 761.90M | 758.71M |
| Income Before Tax Ratio | 72.20% | 10.28% | 54.21% | 80.21% | 135.67% | 84.57% | 84.06% | 40.58% | 45.91% |
| Income Tax Expense | 0.00 | 187.23M | 762.45M | 1.15B | 349.33M | 433.37M | 542.66M | 195.99M | 177.28M |
| Net Income | 1.13B | 42.83M | 478.75M | 495.20M | 2.35B | 1.38B | 1.21B | 565.91M | 581.43M |
| Net Income Ratio | 48.20% | 1.91% | 20.91% | 23.34% | 129.45% | 76.76% | 75.72% | 30.14% | 35.19% |
| EPS | 3.41 | 0.10 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
| EPS Diluted | 2.53 | 0.10 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
| Weighted Avg Shares Out | 447.60M | 437.96M | 414.79M | 375.44M | 365.90M | 354.18M | 354.18M | 607.04M | 607.04M |
| Weighted Avg Shares Out (Dil) | 602.90M | 437.97M | 414.80M | 375.46M | 365.90M | 354.18M | 354.18M | 607.04M | 607.04M |
2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips
The benchmark stock indexes keep climbing to new heights, but there are plenty of attractive wallflowers at this dance. A couple of overlooked dividend payers offer high yields and reliable dividend payout growth, but you wouldn't know it by looking...
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 (^GSPC 0.24%) index rose a whopping 57.1% higher.
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:
Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks from the past week, aiming to spark ideas and discussions among retail investors. Veradigm Inc. is undervalued due to regulatory pressures, but has significant upside potential with strategic buyers potentially paying mid-...
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize...
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade
Royalty Pharma: Massive Opportunity Ahead
Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow despite challenges, with Vertex's Venza triple development posing potential headwinds. With...
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation's (Nasdaq: GERN) RYTELO for $125 million in cash upfront.
Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Royalty Pharma plc (RPRX) Q3 2024 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants George Grofik - SVP, Head, Investor Relations and Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP, Head-Research and Investments...
Source: https://incomestatements.info
Category: Stock Reports